Sign in Subscribe
Chemotherapy

Chemotherapy as a Double-Edged Sword: Modulating Tumor-Associated Cytokine and Chemokine Responses in Ovarian Cancer

Strategic Insights

— 1 min read

Researchers at the First Affiliated Hospital of Jinan University have identified the dual roles of chemotherapy in modulating cytokine dynamics in ovarian cancer, providing valuable insights for addressing resistance and improving combination therapies. The study, published in the International Journal of Cancer, reveals that platinum-based agents and taxanes can trigger cytotoxic effects but also influence the networks of pro- and anti-tumor cytokines, playing a role in both treatment efficacy and resistance.

Key Takeaways:

  • Ovarian cancer is one of the most lethal gynecological malignancies, with high recurrence rates and chemoresistance posing significant challenges to effective treatment.
  • Platinum-based agents, such as cisplatin and carboplatin, along with taxanes, including paclitaxel and docetaxel, represent fundamental therapies for ovarian cancer.
  • Chemotherapy not only triggers cytotoxic effects but also influences the networks of pro- and anti-tumor cytokines, playing a role in both treatment efficacy and resistance.
  • Key mediators like interleukin (IL) 6, IL-8, transforming growth factor-beta, and C-X-C motif ligand 2 drive survival pathways and chemoresistance in ovarian cancer.
  • Chemotherapy might enhance anti-tumor immunity via interferon-gamma and IL-12, revealing the potential for synergistic chemoimmunotherapy.
  • The study highlights the complex interactions between chemotherapy and the tumor microenvironment, emphasizing the need for a more comprehensive understanding of these dynamics.

Statistics:

  • Ovarian cancer is estimated to account for approximately 3% of all female cancer diagnoses worldwide.
  • Platinum-based agents and taxanes are used in approximately 70% of ovarian cancer treatment regimens.
  • Chemoresistance develops in up to 50% of cases, significantly reducing treatment efficacy.
  • The study investigates the role of interleukin (IL) 6, IL-8, transforming growth factor-beta, and C-X-C motif ligand 2 in mediating chemoresistance in ovarian cancer.

Sources:

  • NewsRx. First Affiliated Hospital of Jinan University Describes Findings in Ovarian Cancer (Chemotherapy as a double-edged sword: Modulation of tumor-associated cytokine and chemokine responses in ovarian cancer). OBGYN & Reproduction Week. September 29, 2025; p 381.
  • International Journal of Cancer, 2025. (Wiley-Blackwell - www.wiley.com/; International Journal of Cancer - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0215)

Read more